Tarsus Pharmaceuticals (NASDAQ: TARS) insider transactions

In the twelve months to 10 November 2026, executives and directors of Tarsus Pharmaceuticals reported 59 open-market sales of 271,557 shares ($20.0m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Tarsus Pharmaceuticals shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
15 September 2026	Pyott David E I	Director	Option exercise	+201	—	9,575	Form 4
15 September 2026	Yarno Wendy L	Director	Option exercise	+302	—	16,956	Form 4
15 September 2026	Link William J Phd	Director	Option exercise, 10b5-1 plan	+201	—	106,987	Form 4
15 September 2026	Link William J Phd	Director	Open-market sale, 10b5-1 plan	−11,675	$78.33	95,312	Form 4
15 September 2026	Link William J Phd	Director	Open-market sale, 10b5-1 plan	−759	$79.00	94,553	Form 4
15 September 2026	Link William J Phd	Director	Open-market sale, 10b5-1 plan	−66	$80.01	94,487	Form 4
4 September 2026	Neervannan Seshadri	Chief Operating Officer	Open-market sale, 10b5-1 plan	−4,564	$85.00	78,532	Form 4
4 September 2026	Azamian Bobak R.	President/CEO and Board Chair	Open-market sale, 10b5-1 plan	−7,100	$90.27	830,891	Form 4
4 September 2026	Azamian Bobak R.	President/CEO and Board Chair	Open-market sale, 10b5-1 plan	−2,900	$91.27	827,991	Form 4
4 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−5,387	$85.00	7,933	Form 4
4 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−5,386	$90.00	2,547	Form 4
4 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,590	$85.00	3,180	Form 4
4 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,590	$90.00	1,590	Form 4
2 September 2026	Azamian Bobak R.	President/CEO and Board Chair	Open-market sale, 10b5-1 plan	−10,000	$80.06	837,991	Form 4
2 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−5,387	$80.00	13,320	Form 4
2 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,590	$80.00	4,770	Form 4
1 September 2026	Lin Elizabeth Yeu	Chief Medical Officer	Open-market sale, 10b5-1 plan	−4,601	$73.86	18,707	Form 4
17 June 2026	Azamian Bobak R.	President/CEO and Board Chair	Open-market sale, 10b5-1 plan	−4,582	$61.24	853,409	Form 4
17 June 2026	Azamian Bobak R.	President/CEO and Board Chair	Open-market sale, 10b5-1 plan	−5,418	$61.81	847,991	Form 4
16 June 2026	Farrow Jeffrey S	See Remarks	Open-market sale	−14,396	$60.95	56,801	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Tarsus Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.